These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17545614)

  • 1. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
    Sui M; Huang Y; Park BH; Davidson NE; Fan W
    Cancer Res; 2007 Jun; 67(11):5337-44. PubMed ID: 17545614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
    Jiang D; Huang Y; Han N; Xu M; Xu L; Zhou L; Wang S; Fan W
    Cancer Lett; 2014 May; 346(2):292-9. PubMed ID: 24462822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
    Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
    Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
    Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
    Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells.
    Shi J; Chen Y; Chen W; Tang C; Zhang H; Chen Y; Yang X; Xu Z; Wei J; Chen J
    J Cell Mol Med; 2018 Nov; 22(11):5220-5230. PubMed ID: 30179299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.
    Jiang Z; Guo J; Shen J; Jin M; Xie S; Wang L
    J Exp Clin Cancer Res; 2012 May; 31(1):42. PubMed ID: 22553917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
    Zhou Y; Inaba S; Liu J
    Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest.
    Dziadyk JM; Sui M; Zhu X; Fan W
    Anticancer Res; 2004; 24(1):27-36. PubMed ID: 15015572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
    Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
    Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
    Sun X; Li D; Yang Y; Ren Y; Li J; Wang Z; Dong B; Liu M; Zhou J
    J Pathol; 2012 Mar; 226(4):666-73. PubMed ID: 21989536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
    Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of paclitaxel effect by resveratrol in human breast cancer cells by counteracting the 17β-estradiol/estrogen receptor α/neuroglobin pathway.
    Cipolletti M; Montalesi E; Nuzzo MT; Fiocchetti M; Ascenzi P; Marino M
    J Cell Physiol; 2019 Apr; 234(4):3147-3157. PubMed ID: 30421506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel.
    Czeczuga-Semeniuk E; Jarzabek K; Lemancewicz D; Wołczyński S
    Gynecol Endocrinol; 2009 May; 25(5):287-93. PubMed ID: 19340624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.
    Dong XL; Xu PF; Miao C; Fu ZY; Li QP; Tang PY; Wang T
    Biomed Pharmacother; 2012 Feb; 66(1):70-5. PubMed ID: 22264882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.